{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:28:03Z","timestamp":1791851283087,"version":"4.3.4"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.550205","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T10:00:48Z","timestamp":1599040848000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir\/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan"],"prefix":"10.3389","volume":"11","author":[{"given":"Saima","family":"Mushtaq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayyab Saeed","family":"Akhter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamir","family":"Sohail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobia","family":"Manzoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.180257","article-title":"The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses","volume":"5","author":"Al Kanaani","year":"2018","journal-title":"R. Soc. Open Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.7314\/APJCP.2016.17.5.2407","article-title":"Virological response to conventional interferon therapy combined with ribavirin against various HCV genotypes in Khyber Pakhtunkhwa, Pakistan","volume":"17","author":"Ali","year":"2016","journal-title":"Asian Pacific J. Cancer Prev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3851\/IMP3061","article-title":"Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials","volume":"22","author":"Arias","year":"2017","journal-title":"Antivir. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/apt.13300","article-title":"Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 US Veterans","volume":"42","author":"Backus","year":"2015","journal-title":"Alimentary Pharmacol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1053\/j.gastro.2018.10.024","article-title":"Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges","volume":"156","author":"Baumert","year":"2019","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jhep.2018.09.018","article-title":"Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir\/sofosbuvir in hepatitis C genotype 2 and 3","volume":"70","author":"Belperio","year":"2019","journal-title":"J. Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1080\/14656566.2016.1182156","article-title":"Prevention and management of treatment failure to new oral hepatitis C drugs","volume":"17","author":"Ben\u00edtez-Guti\u00e9rrez","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.jhep.2015.08.010","article-title":"Management of direct-acting antiviral agent failures","volume":"63","author":"Buti","year":"2015","journal-title":"J. Hepatol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.6537","article-title":"Efficacy and Safety of Sofosbuvir-Velpatasvir combination in Hepatitis C Virus-infected Pakistani Patients without Cirrhosis or with Compensated Cirrhosis: A Prospective, Open-label Interventional Trial","volume":"12","author":"Butt","year":"2020","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175562","article-title":"Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan","volume":"12","author":"Capileno","year":"2017","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.4254\/wjh.v7.i12.1617","article-title":"Predictive factors associated with hepatitis C antiviral therapy response","volume":"7","author":"Cavalcante","year":"2015","journal-title":"World J. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","author":"Chung","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/apt.13925","article-title":"Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection","volume":"45","author":"Cornberg","year":"2017","journal-title":"Alimentary Pharmacol. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"New Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/cid\/ciw119","article-title":"Real-world sustained virologic response rates of sofosbuvir-containing regimens in patients coinfected with hepatitis C and HIV","volume":"62","author":"Del Bello","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B16","first-page":"226","article-title":"Direct-actng antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital","volume":"31","author":"del Rio-Valencia","year":"2018","journal-title":"Rev. Espa\u00f1ola Quimioterapia"},{"key":"B17","article-title":"Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population","volume":"60","author":"Dieterich","year":"2014","journal-title":"Hepatology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann. Internal Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"S209","DOI":"10.1016\/S0168-8278(16)01726-8","article-title":"High sustained virological response rates using generic direct acting antiviral treatment for hepatitis C, imported into Australia","volume":"64","author":"Freeman","year":"2016","journal-title":"J. Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s12664-017-0763-3","article-title":"Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience","volume":"36","author":"Goel","year":"2017","journal-title":"Indian J. Gastroenterol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1111\/liv.13383","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme","volume":"37","author":"H\u00e9zode","year":"2017","journal-title":"Liver Int."},{"key":"B22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S2055-6640(20)30691-9","article-title":"Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C","volume":"2","author":"Hill","year":"2016","journal-title":"J. Virus Eradicat."},{"key":"B23","first-page":"197a","article-title":"Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort: 45","volume":"60","author":"Jensen","year":"2014","journal-title":"Hepatology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5812\/jjm.86428","article-title":"Molecular Epidemiology of Hepatitis C Virus Genotypes Among Chronically Infected Patients in Pakistan","volume":"12","author":"Khan","year":"2019","journal-title":"Jundishapur J. Microbiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1093\/ije\/dyx270","article-title":"Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination","volume":"47","author":"Lim","year":"2018","journal-title":"Int. J.\u00a0Epidemiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/j.bmcl.2019.04.027","article-title":"Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi\u00ae and Epclusa\u00ae","volume":"29","author":"Link","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance\u2013associated substitutions: State of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.23750\/abm.v90i2.8374","article-title":"Efficacy of 12-weeks velpatasvir plus sofosbuvir-based regimen in HCV-naive subjects with mild fibrosis: a meta-analysis","volume":"90","author":"Mariantonietta","year":"2019","journal-title":"Acta Bio Med.: Atenei Parmensis"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25745","article-title":"Direct-acting antiviral agents in the treatment of chronic hepatitis C\u2014Real-life experience from clinical practices in Pakistan","volume-title":"J. Med. Virol.","author":"Mushtaq","year":"2020"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/apt.14428","article-title":"Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt","volume":"47","author":"Omar","year":"2018","journal-title":"Alimentary Pharmacol. Ther."},{"key":"B33","volume-title":"Regional action plan for the implementation of the global health sector strategy on viral hepatitis 2017\u20132021","author":"Organization","year":"2017"},{"key":"B34","unstructured":"Progress report on access to hepatitis C treatment: focus on overcoming barriers in low-and middle-income countries\n            OrganizationW. H.\n          World Health Organ.2018"},{"key":"B35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"Pawlotsky","year":"2018","journal-title":"J.\u00a0Hepatol."},{"key":"B36","first-page":"e4","article-title":"Treatment of hepatitis B and C through national programme-an audit","volume":"63","author":"Qureshi","year":"2013","journal-title":"J. Pak Med. Assoc."},{"key":"B37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1478-3231.2011.02540.x","article-title":"A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt","volume":"31","author":"Sievert","year":"2011","journal-title":"Liver Int."},{"key":"B38","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/jgh.13628","article-title":"Results of sofosbuvir-based combination therapy for chronic hepatitis C cohort of Indian patients in real-life clinical practice","volume":"32","author":"Sood","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1517\/14656566.2016.1112790","article-title":"New hepatitis C therapies for special patient populations","volume":"17","author":"Soriano","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.pharmthera.2017.10.009","article-title":"Direct antiviral agents (DAAs)-A new age in the treatment of hepatitis C virus infection","volume":"183","author":"Spengler","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"New Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1053\/j.gastro.2015.10.013","article-title":"Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection","volume":"150","author":"Sulkowski","year":"2016","journal-title":"Gastroenterology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.4269\/ajtmh.17-0019","article-title":"Importance and contribution of community, social, and healthcare risk factors for hepatitis C infection in Pakistan","volume":"97","author":"Trickey","year":"2017","journal-title":"Am. J. Trop. Med. Hygiene"},{"key":"B44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.20517\/2394-5079.2018.31","article-title":"Efficacy and safety of generic daclatasvir+ sofosbuvir\u00b1ribavirin in treatment of genotype 3 infected hepatitis C patients-a real life experience from Pakistan","volume":"4","author":"Umar","year":"2018","journal-title":"Hepatoma Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.3748\/wjg.v22.i4.1684","article-title":"Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data","volume":"22","author":"Umer","year":"2016","journal-title":"World J.\u00a0Gastroenterol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1136\/gutjnl-2016-312444","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort","volume":"65","author":"Welzel","year":"2016","journal-title":"Gut"},{"key":"B47","doi-asserted-by":"publisher","first-page":"8050","DOI":"10.3748\/wjg.v22.i35.8050","article-title":"Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12","volume":"22","author":"Werner","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003004","article-title":"Systematic review and network meta-analysis of randomized controlled trials: comparative effectiveness and safety of direct-acting antiviral agents for treatment-naive hepatitis C genotype 1","volume":"95","author":"Zhu","year":"2016","journal-title":"Medicine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.550205\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T10:00:55Z","timestamp":1599040855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.550205\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":48,"alternative-id":["10.3389\/fphar.2020.550205"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.550205","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,2]]},"article-number":"550205"}}